Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms

[1]  H. Koo,et al.  Erythrocyte thiopurine methyltransferase activity in a Korean population. , 1996, British journal of clinical pharmacology.

[2]  M. Relling,et al.  Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. , 1996, Pharmacogenetics.

[3]  J. Aarbakke,et al.  Thiopurine methyltransferase activity in a Korean population sample of children , 1996, Clinical pharmacology and therapeutics.

[4]  W. Evans,et al.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.

[5]  R. Chadwick,et al.  Heterozygote and mutation detection by direct automated fluorescent DNA sequencing using a mutant Taq DNA polymerase. , 1996, BioTechniques.

[6]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics: Identification of a novel variant allele , 1996 .

[7]  R. Weinshilboum,et al.  Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. , 1996, DNA and cell biology.

[8]  L. Kalaydjieva,et al.  Double mutant alleles: are they rare? , 1995, Human molecular genetics.

[9]  M. Relling,et al.  Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. , 1995, Blood.

[10]  R. Weinshilboum,et al.  Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[11]  M. Relling,et al.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Weinshilboum,et al.  Segregation analysis of human red blood cell thiopurine methyltransferase activity , 1995, Genetic epidemiology.

[13]  R. Weinshilboum,et al.  Purine substrates for human thiopurine methyltransferase. , 1994, Biochemical pharmacology.

[14]  J. Lilleyman,et al.  Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia , 1994, The Lancet.

[15]  C. Pui,et al.  Thiopurine methyltransferase activity in American white subjects and black subjects , 1994, Clinical pharmacology and therapeutics.

[16]  J. Lilleyman,et al.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. , 1993, Archives of disease in childhood.

[17]  R. Weinshilboum,et al.  Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. , 1993, Molecular pharmacology.

[18]  J. Gummert,et al.  Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.

[19]  R. Weinshilboum.  Methylation pharmacogenetics: thiopurine methyltransferase as a model system. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  R. Weinshilboum,et al.  Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. , 1992, Pharmacogenetics.

[21]  E. Utsi,et al.  Interethnic difference in thiopurine methyltransferase activity , 1992, Clinical pharmacology and therapeutics.

[22]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[23]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[24]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[25]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[26]  R. Weinshilboum,et al.  Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.

[27]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.

[28]  R. Weinshilboum,et al.  Human kidney thiopurine methyltransferase. Purification and biochemical properties. , 1983, Biochemical pharmacology.

[29]  R. Weinshilboum,et al.  Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. , 1982, The Journal of pharmacology and experimental therapeutics.

[30]  Stephen M. Mount,et al.  A catalogue of splice junction sequences. , 1982, Nucleic acids research.

[31]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[32]  R. Weinshilboum,et al.  Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. , 1978, Clinica chimica acta; international journal of clinical chemistry.

[33]  C. Remy.  Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. , 1963, The Journal of biological chemistry.